2012-11-15 17:47:54 -

By Jake King

After declines in the first half of the week, shares of Threshold
Pharmaceuticals (NASDAQ:THLD) rebounded on Thursday morning following an update
on the company's ongoing Phase 2 trial of TH-302 (403 Trial) in soft tissue
sarcoma. The drug in combination with doxorubicin demonstrated a median
progression free survival (PFS) of 6.7 months, a median overall survival (OS) of
21.5 months, and an acceptable safety profile. In a single-arm component of the
study (roughly half of the total patient population) patients continued
treatment with TH-302 as a single agent following the doxorubicin combination
treatment; median PFS was 3.7 months, and median OS was 18.0 months in the
maintenance extension. The Phase 2 supports the ongoing Phase 3 '406 Trial', in
which TH-302 plus doxorubicin is being compared to doxorubicin   alone as a first-
line soft tissue sarcoma treatment; interim data is expected in 1H13. That trial
is being carried out under a Special Protocol Assessment with the FDA.

Threshold, however, bears the brunt of upcoming trial results from multiple
competitors. Continue reading here.

Click here to see the full article at PropThink.com.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at  www.propthink.com.

Disclaimer:

You should assume that as of the publication date of any report or letter,
PropThink, LLC and persons or entities with whom it has relation ships
(collectively referred to as "PropThink") has a position in all stocks (and/or
options of the stock) covered herein that is consistent with the position set
forth in our research report. Following publication of any report or
letter, PropThink intends to continue transacting in the securities covered
herein, and we may be long, short, or neutral at any time hereafter regardless
of our initial recommendation. To the best of our knowledge and belief, all
information contained herein is accurate and reliable, and has been obtained
from public sources we believe to be accurate and reliable, and not from company
insiders or persons who have a relationship with company insiders. PropThink was
not compensated to publish this article. Our full disclaimer is available
at  www.propthink.com/disclaimer.




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: PropThink via Thomson Reuters ONE
[HUG#1658555]